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Abstract
Introduction Polyacrylamide hydrogel (PAHG, Bulkamid®)
is a promising urethral bulking agent. This multicenter study
was carried out to evaluate safety and efficacy of Bulkamid®
for female stress and mixed urinary incontinence.
Methods Submucosal injection ofBulkamid® was performed
in 135 women with urinary incontinence (stress, 67; mixed,
68) followed for 12 months. Forty-seven had a reinjection
(35%).
Results At 12 months, the subjective response rate was 66%.
Incontinence episodes/24 h and urine leakage g/24 h
decreased significantly (from 3.0 to 0.7 and 29 g to 4 g,
respectively). Additionally, the median International Consul-
tation on Incontinence Questionnaire score was reduced to
approximately 50%, and the overall quality of life visual
analogue scale score was decreased significantly (from 72 to
20). Efficacy was very similar between patients with stress
and mixed incontinence. Thirty treatment-related adverse
events were registered. The most frequent was urinary tract
infection (n=10). No polyacrylamide hydrogel-specific
adverse events were seen.
Conclusions Bulkamid® is an effective and safe bulking




Intramural urethral bulking therapy for female urinary incon-
tinence has become increasingly popular among physicians
and patients due to its minimally invasive nature. Recent
advances have shed light on the working mechanism of
bulkingagents[1], and a recent clinical study has documented
that bulking therapy is more effective than conservative
treatment in terms of pelvic floor training [2].
Many agents of different make and tissue interaction have
been used for urethral bulking. However, in terms of efficacy,
no clear conclusions can be drawn from trials comparing
alternative agents at the moment [3]. Safety concerns have
been raised with regard to specific agents because of
migration [4], hypersensitivity [5], urethral erosion [6],
pseudocysts/abscess [7], and granuloma formation [8–11].
Materials such as paraffin, polytetrafluroethylene, autologous
fat, and most recently, ethylene vinyl alcohol (Tegress®) and
hyaluronic acid/dextranomer copolymer (Zuidex®) have
been abandoned because of safety issues.
In 2006, polyacrylamide hydrogel (PAHG) Bulkamid®
was introduced in Europe as a promising new urethral
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DOI 10.1007/s00192-010-1214-1bulking agent [12]. It is a polymer gel consisting of 2.5%
cross-linked polyacrylamide and 97.5% water for injection,
which is atoxic [13, 14] and resistant to degradation [15,
16]. It has a widespread use in ophthalmic surgery, drug
treatment, food packaging, and water purification [17].
PAHG has been used in plastic surgery for esthetic
purposes in the former Soviet Union and China for the
past 15 to 20 years, and in Europe for the past 7 [18].
According to these studies, the gel stays within soft tissues
for at least 8 1/2 years after the injection, and gives rise to
little or no tissue reaction without capsular fibrosis or
calcification [15]. A recent study in rabbits has shown that
the bulking effect is preserved for at least for 7 months [13],
and a study in pigs has documented that PAGH is a stable
viscoelastic bulking agent which is being integrated within
its host tissue by vessel ingrowth [16].
The aim of the present study was to investigate the clinical
efficacy and safety of PAHG (Bulkamid®) in a larger cohort
of women with stress or mixed urinary incontinence.
Materials and methods
The study was an open, noncomparative, multicenter, and
multinational study including 10 centers in five countries;
two centers in Denmark, two in Sweden, one in Finland,
four in UK, and one in Germany. The study was performed
in accordance with International Conference on Harmoni-
sation Good Clinical Practice Guidelines.
Methods, definitions, and units conform to the standards
recommended by the International Continence Society,
except where specifically noted [19].
Patient characteristics
Women aged ≥18 years were eligible to participate if they had
symptomatic stress or mixed incontinence for ≥12 months,
and ≥1 incontinence episode per 24 h, measured by a 3-day
micturition diary. Additional requirements were a maximum
flow rate of ≥15 ml/s, a post-void residual urine volume
(PVR) of ≤100 ml, a bladder capacity ≥300 ml based on the
micturition diary (measured over 3 days) normal diuresis
(<40 ml/kg per 24 h), and no pelvic organ prolapse ≥ stage 2.
Women were excluded if they had an acute urinary tract
infection (UTI), allergic reaction to local anesthesia and
antibiotics used for prophylaxis, had previous surgery for
incontinence including bulking, received ongoing medication
for incontinence (except anticholinergics at a constant dose
for >4 weeks), were treated with systemic corticosteroids, or
suffered from active autoimmune or connective tissue
diseases, or were pregnant.
All women had a screening visit including full medical
history, a physical and pelvic examination including genital
prolapse (pelvic organ prolapse quantification) score,
uroflowmetry, PVR measurement, and urine dipstick test
(if positive with culture and sensitivity). The screening visit
was followed by a baseline visit collecting data from the 24-
h pad-weighting test and estimating bladder capacity, number
of micturitions, stress and urge incontinence episodes;
diuresis were estimated based on a 3-day micturition diary.
In addition, the International Consultation on Incontinence
Questionnaire (ICIQ) [20], as well as a patient quality of life
(QoL) visual analogue scale (VAS) score [21] was filled in.
Treatment with PAHG was performed at the baseline visit or
within 3 days, and no later than 8 weeks from the screening
visit. In case of a UTI at the baseline visit, a new baseline
visit could be rescheduled one time.
Treatment and follow-up
The PAHG injection was administered under local anesthesia.
The women were in the lithotomy position, and a total of
10 ml of 5% Lidocaine was injected into the wall of the
urethra at 3 and 9 o’clock positions. PAHG was injected
transurethrally into the submucosa under urethroscopic
control using a 23 G×120-mm needle with 1 cm markings
to enable correct placement of the injection (Bulkamid®
cystoscope, Fig. 1).
Two or three deposits (0.2–0.8 ml each) were placed
0.5–1 cm distal to the bladder neck at 2, 6, and 10 o’clock
positions. The needle was re-sited if the injection appeared
Fig. 1 The Urethroscope, connected to the rotatable sheath, with
inflow/outflow tubings. The needle (23G x 12 cm) is placed in the
working-canal connected to a 1 ml syringe with Bulkamid
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of PAHG into the bladder or urethral lumen. After
satisfactory urethral occlusion, the bladder was emptied
via the endoscope. During injection, the women received a
prophylactic antibiotic treatment, e.g., an i.v. dose of
cefuroxime (1.5 g). They were discharged after successful
voiding (PVR <100 ml, assessed by ultrasonography).
Thewomenwerereevaluated1,6,and12monthslater.The
efficacy assessment included patient subjective perception
(“cured”, “improved”, “not changed”,o r“worsened”)[ 22]),
number of incontinence episodes/24 h, 24-h pad-weighting
testing, ICIQ, and VAS score on QoL. Furthermore, urine
stix were performed, and measurement of PVR was carried
out.
Patientsconsidering themselves for “cured” or “improved”
weredefinedasresponders.Iftheyhadnotgainedsatisfactory
benefit from the first injection at the first-month follow-up
visit, they were offered a second treatment within 8 weeks
period.
Adverse events were classified as serious or non-serious,
and judged to be either related (ADE) or unrelated to the
study treatment (AE).
Data analyses and statistics
The sample size was estimated based on a binomial
distribution. Assuming a success rate of PAHG treatment
of at least 50% with a maximum of uncertainty of 10%, the
trial should include a minimum of 100 patients. Assuming a
dropout rate of 20%, a total of 125 subjects should be
enrolled into the study.
All analyses were based on the intention-to-treat (ITT)
analysis set, which was defined as patients that have
received at least one PAHG injection.
The subjective responder rate at 6 and 12 months was
estimated using a logistic regression with time as fixed effect.
Change from baseline in the ICIQ scores was analyzed by the
Wilcoxon signed-rank test. Each of the three ICIQ questions,
aswellastheirtotalsumscore,wasanalyzedseparately.Urine
leakage (pad test) was analyzed in an ANOVA model with
time as fixed effect. Number of incontinence episodes was
evaluated in a generalized linear model for repeated measure-
ments assuming a Poisson distribution and a covariance
matrix with compound symmetry structure. Estimated
changes from baseline are presented as ratios (estimate post-
baseline compared to baseline). Three VAS scores measuring
QoL asa resultofoverall incontinence,stressincontinence,or
urge incontinence were analyzed separately in an ANOVA
model with time and baseline VAS score as fixed effects.
PVR, the proportion of subjects receiving a second injection
of PAHG, duration of the injection procedure, and the
surgeons’ satisfaction with the injection technique were
summarized using descriptive statistics.
Missing values were imputed with the last observation
carried forward (LOCF) in the analyses of the responder
rate and ICIQ. For repeated measurements, missing values
were not imputed with the LOCF. Instead, they were dealt
with inside the model. Repeated measurement analyses
were performed for urine leakage (pad test), incontinence
episodes, and QoL parameters.
Additional analyses Additional analyses were performed to
evaluate the effect of other variables in the treatment
outcome. Responder rate was assessed on data sets
stratified by: type of urine incontinence (stress versus
mixed), number of treatments (one vs two), and number
of PAGH injection procedures performed per center (<15
injections (low volume) versus ≥15 injections (high
volume)). Analyses were based on a logistic regression
model with missing responder values imputed with LOCF.
As supportive analysis of the primary analysis, the logistic
regression model was expanded by incorporating the
covariates age and BMI as continuous variables, in separate
analyses.
Ethical assurances The study was conducted in accordance
with the Declaration of Helsinki II 1964, as amended in
Scotland, October 2000, the Council Directive 93/42/EEC
of 14 June 1993 concerning medical devices (commonly
known as the Medical Device Directive), and the interna-
tional ISO standard ISO/DIS 14155-1+2:2003 clinical
investigation of medical devices for human subjects. The
clinical investigation plan was submitted to all local ethics
committees. Written informed consent was obtained from
all patients after written and verbal information about the
study, procedures, potential risks, or inconveniences, and
expected benefits.
Results
One hundred thirty-five women (67 with stress and 68 with
mixed incontinence) were recruited and treated with PAHG.
Table 1 outlines the patients’ demographic and baseline
measurements.
Ninety-eight patients completed the study, 36 withdrew,
and one patient failed to attend only the 12 months follow-up
visit. One patient withdrew due to an AE (aggravated urine
incontinence), 11 due to insufficient effect, and six due to
protocol violations. Three patients were lost to follow-up,
three withdrew their informed consent, and 12 withdrew for
other reasons.
The ITT analysis set included 135 patients, and the per
protocol analysis set included 94 patients (four of the 98
patients who completed the study had protocol violations, but
were allowed to continue in the safety analyses of the study).
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treatment was 1.5 ml (range 0.8–3 ml). The median volume
per deposit was 0.5 ml.
Efficacy
Responder rates (cured/improved) after 1 month, 6 months,
and 12 months were 87%, 71%, and 66%, respectively. The
corresponding fractions of totally cured patients were 27%,
16%, and 24%, respectively. At 12 months, 19 patients
were categorized as non-responders, 17 showed “no-
change”, and two worsening of symptoms. The subjective
responder rate at 12 months was 70% among patients with
stress incontinence compared to 63% among those with
mixed incontinence. The responder rate at 12 months was
higher among those receiving one treatment than among
receiving two (71% vs 57%, p=0.0058). The responder rate
after 12 months was 58% among women treated at a low
volume center (<15 injections), and 69% among those
treated at a high volume center (≥15 injections). This
difference is of borderline statistical significance (p=0.0974).
No significant relationships could be found between the
responder rate and age, BMI, or injected PAGH volume.
The median ICIQ score (three questions shown in
Table 2) decreased by approximately 50% at 1, 6, and
12 months follow-up (p<0.0001). The overall QoL VAS
score decreased significantly from a baseline median of 72
to 19, 22, and 20 after 1 month, 6 months, and 12 months
follow-up, respectively. The corresponding stress compo-
nent score was improved from a baseline median of 81 to
18, 22, and 18, and the urge component score from a
baseline median of 40 to 9, 7, and 6 after 1, 6, and
12 months, respectively.
The median number of incontinence episodes/24 h
decreased in the group as a whole from 3.0 (range 0.0–14.7)
at baseline to 0.7 (range 0.0–16.0) at 1 month, 6 months, and
12 months (p<0.0001 vs baseline). In 72% of the patients,
number of incontinence episodes decreased by at least 50%.
The median number of stress episodes decreased from 1.3
(range 0–8) at baseline to 0.0 (range 0.0–13.0) at 12 months,
while the median number of urge incontinence episodes
decreased from 0.7 (range 0.0–8.7) at baseline to 0.0 (range
0.0–7.7) at 12 months.
The median urine leakage/24 h was significantly reduced
after treatment in the group as a whole, ranging from 29 g
(range 1–552) at baseline to 4g (range 0–347) at 1 month, 5g
(range0–150)at6months,and4g(range0–144)at12months
(p<0.0001 vs baseline). Thus, the urine leakage/24 h was
reduced by approximately 85%, and 69% of the patients had
at least 50% decrease in urine leakage.
The median PVR was unchanged during the study
(baseline 20 ml (range 0–100), 1 month, 8 ml (range 0–158),
6 months, 12 ml (range 0–116), and 12 months, 11 ml (range
0–131)).
The total number of injections was 182, as 47 out of the
135 patients (35%) received PAHG reinjections.
The injection procedure took a median time of 7 min
(range 2–20 min).
Surgeon satisfaction with the injection procedure was 82
(range 34–100), as measured by VAS of 100 mm.
Safety
Of the 135 patients, 59 experienced an AE. The total
number of events were 96, of which 88 were non-serious
AEs (57 patients), and eight were serious (eight patients).
Out of 88 non-serious AEs, 32 were classified as possibly
(19), or probably (11) related to the treatment (Table 3).
Table 1 Demographic and incontinence-related characteristics of the
ITT population at baseline
Demographic and baseline measurements (N=135)
Median Range
Age (years) 56 29–82
Weight (kg) 76 54–106
BMI (kg/m
2)2 7 2 0 –40
Length of incontinence (years) 6 1–39
Maximal urine flow (ml/s) 28 15–87
Daily diuresis per kg (ml/kg/24 h) 23 9–78
Bladder capacity (ml) 500 250–1,200
PVR (ml) 20 0–100
Table 2 Medians of the ICIQ scores at baseline, 1, 6, and 12 months follow-up in the ITT analysis set
Question Baseline 1month 6months 12months
How often do you leak urine? (range 0–5) 4.0 1.0 2.0 2.0
How much urine do you usually leak? (range 0–6) 4.0 2.0 2.0 2.0
How much does leaking urine interfere with your everyday life? (range 0–10) 8.0 2.0 3.0 3.0
Total (range 0–21) 15.0 6.0 70 7.0
All scores were significantly decreased at all follow-up visits (p<0.0001)
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UTI, nine with postprocedural pain, two of urinary
retention, two of transurethral catheterization, two of
hematuria, two of aggravated incontinence, two of de novo
urge incontinence, and one of injection-site rupture. Two
out of eight serious AEs were treatment-related. Both of
them were urinary retention, which had resolved within 6
and 9 days, respectively.
Discussion
This study has shown that the subjective and objective
outcome at 12 months was similar to that shown in a
previous study of 25 women with stress or mixed urine
incontinence who had been injected with PAGH [12],
taking into account that the present results are based on ITT
analysis. Not surprisingly, the outcome was consistent in
those with pure stress incontinence compared to those with
mixed incontinence. Our results are also comparable to
reports in the literature on bulking agents [23, 24] and
recently published article on Bulkamid [25].
However, this study also showed that patients, who were
treated at centers conducting fewer bulking procedures,
appeared to have a poorer outcome than those treated at
centers conducting higher amount of bulking procedures.
This indicates that there is a learning curve for mastering
injection therapy via an endoscope. Median injection time
was 7 min, emphasizing the ease of the procedure, albeit
performed under direct urethroscopic guidance.
Approximately 1/3 (35%) of the patients received a
second injection within the first 8 weeks comparable to
other studies [23, 24]. Remarkably, we found a significantly
lower cure rate among those patients who received two
treatments, indicating poor effect after the first injection as
a risk factor.
We made no attempts to differentiate between patho-
physiologic factors such as hypermobility and/or intrinsic
sphincter deficiency, as clinical efficiency following bulking
does not seem to differ among these subgroups [26]. Our
study comprised daily routine patients who had only been
treated with noninvasive urodynamic procedures.
However, the right patient population for urethral
injection treatment is still being disputed. Clinical data
show that patients have a general preference for less
invasive forms of therapy, and they are willing to trade a
lower success rate in favor of less invasive procedures [27].
However, pretreatment counseling of the patient is impor-
tant for the clarification of the patient’s expectations in
terms of efficacy and safety.
Polyacrylamide is a polymer made of repeated units of
acrylamide monomers, which are bound covalently by
strong single bonds. This means that the original hazardous
nature of the acrylamide monomer is no longer present. The
linear chain structure of the polymer has further been folded
into a three-dimensional entanglement in principal forming
one huge single and very stable molecule. The total amount
of residual acrylamide monomer in the PAGH Bulkamid is
less than 1 mcg/1-ml product. This amount is lower than
normal daily intake of acrylamide with food and drinking
water. By PAGH injection, the human body is exposed to a
single dose of hardly measurable amount of acrylamide,
and as the molecule is resistant to degradation [28], no
subsequent acrylamide monomer is to be expected.
Acrylamide is classified as a potential carcinogenic
substance since it was shown to induce cancer in rodents.
However, since no conclusive connection was proven even
between intake of high doses of acrylamide and cancer [29,
30], there is no scientific evidence to suspect PAGH being
carcinogenic.
PAHG seems to have many of the ideal properties of a
bulking agent [31]. It does not contain microparticles, which
are shown to provoke a foreign body reaction and give rise
to fibrosis and calcifications, and is highly biocompatible,
not evoking hypersensitivity or granuloma formation. It also
exerts a favorable anatomical integrity by allowing invasion
of macrophages and giant cells that are gradually replaced by
a thin, vessel-bearing fibrous network [15, 16].
The volume of some of the other more common
bulking agents may reduce significantly with time [32].
PAGH, in the opposite, remains stable in volume for years
[15], most likely due to a constant exchange of its water
molecules with those of surrounding tissue extracellular
matrix. [33].
In this study, the material was injected in the upper third
of the urethra, but a recent study seems to indicate that the
Table 3 Summary of the 32 reported treatment-related adverse events
which occurred after 182 injections
Adverse events No. of occurrences
UTI 10





Past void residual >100 ml 2
c
Haematuria 2
Urine incontinence aggravated 2
De novo urge incontinence 2
Injection site laceration 1
Headache 4
aClassified as serious due to hospitalization, recovered within 6 and
9 days, respectively
bNot catheterized
cCatheterized 2 and 4 times within 3 days, respectively
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urethral zone [34].
The median amount of PAHG injected per treatment was
1.5 ml, which is similar to what has been reported
previously [12]. This is however significantly less than
commonly reported from other materials [24]. Too much
material injected per site may increase the risk of material
leakage, either via the injection hole, or due to rupture, or
necrosis of the covering mucosa. No clear standard exists
for the optimal relationship between amount of injected
material and cure rate [24].
PAHG can be visualized ultrasonographically enabling
monitoring during the injection procedure. This is a
significant advantage especially in case of reinjection, but
also in case of material retraction, if too much material has
been injected (author’s personal experience).
PAHG therapy did not change PVR, indicating no
influence on bladder emptying. This is in accordance with
previously reported pressure-flow data [12].
All AEs were generic and not related to the material.
The most common AE (10/182 injections) was UTI,
despite the use of prophylactic antibiotics. Eight patients
experienced problems with bladder emptying—all tran-
sient and possibly due to the injection of the local
anesthetic along the urethra and hence, interference with
its afferent activity. Removal of injected material was not
necessary in any case, and specific injection site or
product-specific AEs were not found, suggesting a high
safety profile of the material.
This study confirms that approximately two out of three
women with uncomplicated stress or mixed incontinence
can be improved or cured by PAHG injection therapy, and
that the results sustain for at least 1 year postoperatively.
The procedure is quick and easy to perform and therefore,
well accepted by the physician. The PAGH safety profile
seems unique, as no injection site or product-specific AEs
were seen.
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